Dr. Mousa contributed to the discovery and development of novel anti-platelet, anti-thrombotic therapies, noninvasive myocardial perfusion (Cardiolite) and thrombus imaging agents. He also contributed to the discovery of ultra-short acting beta blocker, Esmolol, the first Angiotensin Receptor Blocker Losartan. His work has been reported in over 1,000 peer-reviewed publications and holds over 350 US and International Patents. Dr. Mousa is also a Visiting Scholar at the Johns Hopkins University, and holds academic appointments at the State University of New York, and Rensselaer Polytechnic Institute, and President of R&D at Vascular Vision Pharmaceutical Co.

Home-grown strategies focused on educational excellence and innovation where excellence in education and research lead to knowledge-based economic development. Hence, there is a critical need for world class institutions capable of preparing generations that can compete in the global economy. In that regards, regional coordination and cooperation is crucial for the success of educational and research initiatives. The most important asset in the region remains its people. The AES can play an important role in reversing the Brain Drain to Brain Gain.